EUVIMEDEUVIMED entdecken
Crossref

Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy

Yuanying Qian, Weikang Yan, Fan Xu, Yali Liu, Fabao Chen, Yue Lu, Zihan Zhang, Ao Gu, Ruobing Yu, Zhen Fang, Yang Yu, Maolan Li und 3 weitere

Journal of Controlled Release · 2026-11 · 399 · 115355

DOI: 10.1016/j.jconrel.2026.115355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-11. Verfasst von Yuanying Qian und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Paclitaxel, Albumins, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 71 Literaturangaben. Gefördert von: Shanghai Jiao Tong University School of Medicine, Innovative Research Team of High-level Local University in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy has been widely used in cancer treatment, but most of the chemotherapeutic drugs rely mainly on passive accumulation due to lack of target specificity, which may lead to systemic toxicity and limited clinical utility. Recent advances in artificial intelligence-based protein design provide new opportunities for developing precision therapeutics. Here we modify the albumin-bound paclitaxel (Nab-PTX), one of the most widely used drugs in chemotherapies, by applying the fusion proteins of albumin with the de novo designed protein binders targeting human EGFR or HER2. The resulting particles, EGFRmb-Nab-PTX and HER2mb-Nab-PTX, retain the similar physicochemical properties of Nab-PTX while acquiring the receptor-specific binding capacities. The in vitro assays show that both binder-modified Nab-PTX particles have increased uptake and inhibitory effects significantly in the cancer cell lines with high receptor expression levels. Furthermore, the data from a xenograft model, including tumor growth, excised tumor analysis, organ histology, and fluorescence imaging, show that the binder-modified Nab-PTX enhances tumor accumulation, improves tumor suppression, and may reduce off-target exposure compared with the conventional Nab-PTX, suggesting that they may have promising clinical potential in cancer treatment. Overall, this strategy provides an adaptable modular platform for generating albumin-based chemotherapeutic drugs with target specificities, which can be readily customized with diverse target binders to enable precise cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelAlbuminsNeoplasmsAntineoplastic AgentsAntineoplastic Agents, PhytogenicHumansAnimalsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleErbB ReceptorsMice, NudeMice, Inbred BALB CXenograft Model Antitumor AssaysRecombinant Fusion Proteins

Stichwörter der Autor:innen

Albumin-based drugsEGFRHER2Nab-paclitaxelProtein designTargeted drug delivery

Substanzen

PaclitaxelAlbumins130-nm albumin-bound paclitaxelErb-b2 Receptor Tyrosine KinasesErbB ReceptorsERBB2 protein, humanEGFR protein, humanAntineoplastic AgentsAntineoplastic Agents, PhytogenicRecombinant Fusion Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Biliary-Pancreatic Surgery, Renji Hospital…
  • National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
  • School of Life Science, Westlake University, Hangzhou, Zhejiang, China.

Förderung

  • Shanghai Jiao Tong University School of Medicine
  • Innovative Research Team of High-level Local University in Shanghai

Zitieren

APA

Qian, Y., Yan, W., Xu, F., Liu, Y., Chen, F., Lu, Y., Zhang, Z., Gu, A., Yu, R., Fang, Z., Yu, Y., Li, M., Cao, L., Liu, Y., & He, Y. (2026). Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy. Journal of Controlled Release, 399, 115355. https://doi.org/10.1016/j.jconrel.2026.115355

Vancouver

Qian Y, Yan W, Xu F, Liu Y, Chen F, Lu Y, et al. Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy. Journal of Controlled Release. 2026;399:115355. doi:10.1016/j.jconrel.2026.115355

BibTeX
@article{Qian2026,
  author = {Qian, Yuanying and Yan, Weikang and Xu, Fan and Liu, Yali and Chen, Fabao and Lu, Yue and Zhang, Zihan and Gu, Ao and Yu, Ruobing and Fang, Zhen and Yu, Yang and Li, Maolan and Cao, Longxing and Liu, Yingbin and He, Yongning},
  title = {Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {399},
  pages = {115355},
  doi = {10.1016/j.jconrel.2026.115355}
}
Kostenlos starten →